Recursion Pharmaceuticals, Inc. (RXRX)
3.74
+0.20
(+5.65%)
USD |
NASDAQ |
Apr 15, 16:00
3.75
+0.01
(+0.27%)
After-Hours: 20:00
Recursion Pharmaceuticals Research and Development Expense (Annual) : 425.27M for Dec. 31, 2025
Research and Development Expense (Annual) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| Intellia Therapeutics, Inc. | 379.09M |
| Tango Therapeutics, Inc. | 129.88M |
| Geron Corp. | 71.43M |
| Ionis Pharmaceuticals, Inc. | 913.18M |
| Quince Therapeutics, Inc. | 35.38M |